Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older
/
/
Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older

Ipsen

First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity and studied in patients with cerebral palsy

Pivotal study in cerebral palsy patients with lower limb spasticity aged 2 to 17 showed significant improvements in co-primary efficacy endpoints at Week 4 that evaluated Modified Ashworth Scale in ankle plantar flexor muscle tone and Physician’s Global Assessment response to treatment score.

Read the official press release.

Start typing and press Enter to search

Shopping Cart
Skip to content